{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.2","upperLimit":"19.6","value":"16.2"},{"groupId":"OG001","lowerLimit":"16.8","upperLimit":"21.0","value":"18.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from randomization to cancer progression as shown on radiography, according to the RECIST version 1.0 criteria, an increase in the CA125 level according to Gynecologic Cancer InterGroup (GCIG) criteria, global deterioration of health, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients enrolled in the study who did not receive cytoreductive surgery and included in the surgery analysis","id":"OG000","title":"No Cytoreductive Surgery"},{"description":"All patients enrolled in the study who received secondary cytoreductive surgery and were included in the surgery analysis","id":"OG001","title":"Cytoreductive Surgery"}],"paramType":"MEDIAN","populationDescription":"All randomized patients who were eligible for the surgery analysis (data were combined and analyzed according to randomized surgical assignment, regardless of chemotherapy regimen, as pre-specified in the study protocol).","reportingStatus":"POSTED","timeFrame":"Radiographic assessment of disease (in patients with measurable and non-measurable disease) was conducted Every three months for two years and then every 6 months after completion of chemotherapy during the maintenance/surveillance phase.","title":"Progression Free Survival (Surgery Analysis)","type":"SECONDARY","unitOfMeasure":"Months"}